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ABSTRACT 
 
NOVEL ADAPTOR-DEPENDENT DOMAINS PROMOTE PROCESSIVE 
DEGRADATION BY CLPXP 
 
SEPTEMBER 2011 
 
KEITH ROOD, UNIVERSITY OF MASSACHUSETTS AMHERST 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Peter Chien 
 
Protein degradation by ATP dependent proteases is a universally conserved 
process.  Recognition of substrates by such proteases commonly occurs via direct 
interaction or with the aid of a regulatory adaptor protein.  An example of this regulation 
is found in Caulobacter crescentus, where key regulatory proteins are proteolysed in a 
cell-cycle dependent fashion. Substrates include essential transcription factors, structural 
proteins, and second messenger metabolism components.   In this study, we explore 
sequence and structural requirements for regulated adaptor mediated degradation of 
PdeA, an important regulator of cyclic-di-GMP levels. 
Robust degradation of PdeA is dependent on the response regulator CpdRin vivo 
and in vitro.  Here, I structurally identify a novel PAS domain in PdeA that is necessary 
and sufficient for CpdR mediated PdeA degradation.  The PAS domain was found to 
contain a unique dimerization element that is associated with PdeA function.I show 
specifically that PdeA engages ClpXP through C-terminal recognition motifs.  Finally, 
we present evidence that PdeA contains cryptic ClpXP recognition sites that are revealed 
during partial processing.  Due to these uncommon degradation characteristics of PdeA, 
unique proteolytic insights may be gained by investigating this model system. 
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CHAPTER 1 
INTRODUCTION 
 The ClpXP protease plays a role in processing and degrading proteins necessary 
for bacterial cell-cycle progression(5).  Degradation of these substrates occurs either via 
direct interaction with ClpXP or through mediation by an adaptor protein(7,11).  In 
addition, many of these substrates contain terminal recognition sequences specific for 
recognition by ClpXP(3,11,12).Among these substrates is a regulator of cyclic-di-GMP 
levels in the cellknown as PdeA(6).Cyclic-di-GMP is a small molecule known to regulate 
expression of genes relevant to biofilm formation, flagellar activity and translational 
initiation(1,8,9).Furthermore, PdeA is degraded in a cell-cycle dependent fashion, leading 
me to believe it carries a necessary role in proper cell function(6).In this thesis, I 
investigated the structural and degradation characteristics of PdeA.  To do this, I 
conducted my studies in the freshwater bacterium Caulobacter crescentus. 
 C. crescentus is most notably defined by its obligate morphological transition 
during cell division.  At any given time, the bacterium can be found in one of two cell 
types, swarmer or stalk.  Swarmers have an anterior flagellum that allows them to swim 
and search for nutrients.  Stalks are stationary and serve largely to divide and produce 
more swarmer cells(10).  As a result, there are many proteins that are produced and 
degraded during cell division to accommodate either one of these cell types.  One of these 
proteins, PdeA, is degraded in a regulated fashion during cell division and represents a 
model protein for studying the general properties of degradation that go on in such 
division. 
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PdeA has three key domains, two of which are commonly associated with cyclic-
di-GMP regulation.  From N to C-terminus, PdeA has a previously uncharacterized PAS 
domain followed by a degenerate GGDEF domain connected via a short linker to an EAL 
domain (described below and see Figure 1).  The PAS domain is responsible for 
degradation and for an as yet unknown function in PdeA. The degenerate GGDEF and 
EAL domains are associated with regulation of cyclic-di-GMP in PdeA(6). 
A large portion of this thesiscenters on identifyingthe PAS domain and 
characterizing it structurally.  The first indicationI had that PdeA contained an N-terminal 
PAS domain was a simple BLAST search on the first 130 amino acids of PdeA.  
Although the search identified this N-terminal sequence of a PAS domain, I was skeptical 
of the result as PAS domains have little sequence homology.Amino acid sequence 
alignments yield E-values between 1 and 3 and contain 30% or less sequence homology.  
However, PAS domains are structurally homologous(13).  We therefore crystallized the 
first 130 amino acids of PdeA and were able to identify it as a PAS domain.  Later in this 
paper, more detail will be given on the exact characteristics of this domain.    
GGDEF and EAL domains have opposite function in terms of cyclic-di-GMP 
regulation.  GGDEF domains generally cyclize two molecules of GTP into one of cyclic-
di-GMP(8,9).  Alternatively, EAL domains are phosphodiesterase domains that linearize 
cyclic-di-GMP into pGpG(8,9).  Despite containing both of these domains, PdeA appears 
to only actas a phosphodiesterase. likely due to mutations in the degenerate GGDEF 
domain  that disable its ability to cyclize GTP.  However, the GEDEF domain can still 
bind GTP to allosterically regulate the activity in the EAL domain(6). 
 Figure 1: Cyclic-di-GMP Regulation and PdeA Primary Structure: 
di-GMP cyclization and linearization.  Cyclic
domains associated with Diguanylate Cyclases and linearized by EAL domains associated with 
Phosphodiesterases.  Cyclic
and motility.  (bottom) Primary structure of PdeA: left most domain is at N
domain is at C-terminus.  The degenerate GEDEF domain only serves to regulate the EAL 
domain, which linearizes cyclic
 
PdeA levels are regulated through degradation by 
ClpXP is a complex comprised of
tetradecameric protease ClpP
molecules at a given time, but only hydrolyze a single ATP at a rate of approximately 
100 molecules of ATP/minute
unfoldase domains to allow 
ClpP is a serine protease with an active catalytic triad 
it via ClpX(5). 
Substrates that interact directly with ClpX normally contain terminal recognition 
tags, which allow for binding and processing
response regulator, CpdR
contains no obvious terminal or internal recognition tags.  The exact mechanism of CpdR 
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(top) Cartoon of cyclic
-di-GMP is commonly cyclized by GGDEF 
-di-GMP regulates sessility/biofilm formation, cell cycle progression 
-terminus, right most 
-di-GMP. 
the ClpXP protease complex.  
 the hexameric AAA+ unfoldase, ClpX, and the 
(5).  The AAA domains of ClpX can bind up to four ATP 
(14).  Hydrolysis results in conformational changes of the 
pulling of a substrate through the inner pore of the complex.  
that cleaves polypeptides
(5).In the case of PdeA, a single domain 
(4), is required for highly processive degradation.  PdeA 
-
 passed to 
 mediation is currently unknown.  However, 
could mediate ClpX recognition of PdeA by delivering PdeA to the ClpX pore
Figure 2: Model of CpdR-
by an adapter CpdR, which then delivers PdeA to the ClpX pore for recogn
hydrolyzes ATP, unfolding PdeA and directing it into ClpP for degradation
 
In this thesis, I present the struc
CpdR.  Additionally, Iclarify
the cell andquantify the effects that result from truncating or mutating the PdeA structure.  
Tests outside the cell give us a picture of what happens in an isolated degradation system.  
Tests inside the cell give us a picture of how PdeA d
system, as well as insight into the issue of
normal PdeA function. 
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here, I present a model thatsug
 
Mediated PdeA Degradation by ClpXP: A dimer of PdeA is bound 
ition.  ClpX then 
 
tural requirements of PdeA for interaction with 
the characteristics of PdeA degradation outside and inside 
egradation occurs in the livi
 what structural components are required for 
gests CpdR 
(Figure 2). 
ng 
 DEGRADATION DETERMINANTS OF PDEA
 CpdR is a necessary adaptor fo
present a table of degradation assays for various mutants and truncations of PdeA 
described below.  The degradation assay is 
mixture of ClpP, ClpX, an ATP regeneration mix to allow for constant levels of A
substrate of interest and CpdR if necessary. For each protein construct, we tested the 
degradation properties with CpdR present and absent.
Figure 3: Degradation and CpdR Dependence of PdeA Protein Constructs: 
structure, names, and SDS-PA
were done in the presence and absence of 2.5uM CpdR.  Timepoints are indicated above 
degradation experiment sets.  Reaction contents: 0.4uM ClpX(6), 0.8uM ClpP, 4mM ATP, 
75ug/ml Creatine Kinase, 5mM Creatine Phosphate, 1mM GTP, 2.5uM Protein construct.  Half 
lives: WT:19min, R280:24min, E265:105min, G130:76min
 
Our first goal was to determine directionality of PdeA degradation.  To test which 
terminus of PdeA was engaged by ClpX
from arginine and glycine to two aspartic acids (DD).
difficulty recognizingpolar
5 
CHAPTER 2 
 
r PdeA degradation by ClpXP.In Fi
performedin vitro, and includes a simple 
 
GE degradation results of various PdeA protein constructs.  Tests 
 
, I mutated the last C-terminal residues of PdeA 
  It is known that ClpX  has 
 residues as a C-terminal motif(18,19).Therefore, when we 
 made these mutations, no degradation of the
degradation to a lack of recognition by ClpX when the c
close proximity of the ClpX pore
we can make the argument that the C
ClpX. 
Figure 4: Theoretical Model of PdeA
terminal DD mutation which causes ClpX to be unable to recognize PdeA properly, ultimately 
leading to no degradation of the protein.
 
This result was particularly interesting because I had made truncations of PdeA 
prior to the PdeA-DD mutation that could
amino acids.  I made truncations R280, E265 and G130
PdeA thathas arginine 280 as its c
E265 is a version of PdeA 
the EAL domain, as well as the linker connecting the GEDEF and EAL do
is a version of PdeA with glycine 130 as its C
first 130 amino acids.All of these truncations are recognized by ClpX regardless of 
having c-terminal residues that do not represent any known degradation
Furthermore, this result suggests PdeA is able to reengage ClpX after partial processing, 
an event that cannot normally occur in substrates containing only terminal recognition 
tags(7,12)as the once the recognition tag has been degraded, the protea
bind the substrate (Figure 5).
6 
 substrate occurred.  We attribute this lack of 
-terminal DD residues come in 
 (Figure 4).  Since there is no degradation whatsoever, 
-terminus is the initial recognition site of PdeA by 
 
-DD Interaction with ClpXP: PdeA-DD contains a c
 
 be degraded regardless of the C
 (Figure 3).  R280 
-terminal amino acid and contains no EAL domain.  
withglutamic acid 265 as its C-terminal amino acid and lacks 
-terminal amino acid and contains only the 
 tags.  
se can no longer 
This suggests that PdeA either has cryptic recognition tags 
-
-terminal 
is a version of 
mains.  G130 
 that are exposed during partial processing
stop sites. 
Figure 5: Theoretical Model of PdeA
with a c-terminal degradation tag (red) gets degraded partially and is unable to reengage ClpX.  
(bottom)  PdeA is degraded partially, but can still reengage ClpX regardless of its c
amino acids. 
 
My next goal was to isolate the domain on PdeA that interacts with CpdR.  For 
many substrates of proteolysis, the adapter binding site is just upstream of the protease 
recognition site(15,16).However, this was not the case for PdeA.  All of the trun
listed above were degraded in a CpdR
130 amino acids were the key for CpdR interaction.  
thatincluded just the GGDEF domain (L131
histidine tag of roughly the same size as the first 130 amino acids on the N
stand in place of the removed domain.  The SUMO tag has no effect on degradation of 
substrates. Controls were done with a SUMO
CpdR-dependent degradation behavior
not degraded in the presence or absence of CpdR.  Such a result strongly suggests that the 
7 
(20), or that PdeA has no internal degradation 
 
 Partial Protein Reengagement: (top) A protein substrate 
-dependent fashion, suggesting that the N
I made a final truncation 
-E265).  This construct included a SUMO 
-tagged version of E265 that
(Figure 3).  The SUMO-tagged L131
-terminal 
cations 
-terminal 
-terminus to 
shows normal 
-E265 was 
 first 130 amino acids domain arenecessary and sufficient
degradation (Figure 6). 
Figure 6: Theoretical Model of Necessary Domain Interaction: 
domain, CpdR can no longer interact with PdeA for delivery purposes.
 
Next I wanted to know if degradation of PdeA 
same domains.I expressed WT PdeA and a version of PdeA without the first 130 amino 
acids (∆PAS) using a plasmid
native PdeA (∆PdeA cells)
conditions overnight.  The next day, cultures were back diluted to the sameOD
allowed to grow another 90 minutes. The culture was then divided in half and cells were 
pelleted in separate tubes.  One pellet was resuspended in inducing media, while the other 
was resuspended in media containing glucose to turn off protein induction.  Then, 
monitored degradation of the proteins over time
results in figure 7.   
Figure 7: Importance of the PAS Domain 
protein constructs WT PdeA amd 
8 
for CpdR dependent
Without the N
 
in vivo was dependent on these 
-based xylose-inducible systemin Caulobacter
.  Cultures containing these plasmids were grown in inducing 
 using western blotting and 
 
in vivo: (top) Primary structure of tested 
∆PAS. (bottom) Results of in vivo degradation assay in 
 PdeA 
 
-terminal PAS 
 lacking 
600 and 
I 
obtainedthe 
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inducing and non-inducing conditions.  Assay was initiated for each culture at the same 
optical density. 
 
When comparing results of induced strains of PdeA to that of the ∆PAS, I see that the 
neither PdeA nor the ∆PAS protein bands disappear over time. This constant protein level 
is the expected result when protein is under continuously inducing conditions.When 
comparing results of non-induced strains of PdeA to that of ∆PAS, I see that PdeA is 
degraded rapidly as I expect.  Additionally, ∆PAS appears to not be degraded over time 
as the protein band density stays constant over time.  Furthermore, the overall protein 
levels of ∆PAS per OD600 is higher than that of WT PdeA.These results strongly suggest 
that the first 130 amino acids are necessary for PdeA degradation in vivo as well as in 
vitro.  Presumably, degradation cannot happen in the cell because CpdR is unable to 
deliver ∆PAS to ClpXP. 
To better understand the exact effect CpdR has on mediating degradation, I 
sought to investigate the kinetics of a PdeA degradation experiment.  There is more than 
one way an adaptor for proteolysis could function.One mechanism could be to assist in 
tethering a substrate to bring it in closer proximity to the protease(15).  An alternative 
mechanism would be to change conformation of either a substrate or the protease.  A 
conformational change of a substrate could result in better binding to the protease 
recognition site while a conformational change in the protease could result in a higher 
binding capacity for substrates(16).Adaptors could also theoretically affect either the 
affinity of a substrate to bind the protease or the overall rate of degradation of a substrate 
by the protease.   
The mechanism of an adaptor can be indirectly investigated through use of 
Michaelis-Menten kinetics.  The Michaelis-Menten equation relates the initial rate of an 
10 
 
enzymatic reaction to the concentration of a substrate.   In the case of CpdR mediated 
degradation of PdeA, we can equate the rate of reaction to the speed at which CpdR 
delivers PdeA to ClpXP.  This is done by titrating substrate concentration in the 
degradation assay with a constant amount of CpdR.  Plotting the initial degradation rates 
vs. [substrate] gives us a curve that isfit to find the two values relevant to characterizing 
the effect of CpdR.  One of the values is the Vmax, which is the maximum rate of 
degradation by ClpXP.  The other value is the KM, which is the concentration of substrate 
at which the degradation rate is half of the Vmax.  If addition of CpdR changes the 
Vmaxin saturating substrate conditions, then CpdR would serve to change the degradation 
rate, implying enhancement of inherent ClpXP protease activity.  If addition of CpdR 
changes the KM, then CpdR would serve to change the affinity of a substrate to bind 
ClpX.  If addition changes both, then a combination of these models may be present. 
However, the mechanistic effect of a protease adaptor is difficult to quantify if the 
substrate cannot be degraded in the absence of the adaptor.  To quantitatively test the 
effect of CpdR, we made an EGFP labeled version of E265 containing a c-terminal ssrA 
tag.  The ssrA tag(7,12,15)promotes degradation of E265 by ClpXP without requiring 
CpdR.In Figure 8, we see that CpdR serves to decrease the KM of degradation three-fold, 
but has little effect on the Vmax.  This supports our modelthat CpdR serves largely to 
increase the affinity of a substrate to bind ClpX by acting as a simple tether. 
 Figure 8: Kinetics of CpdR Binding: 
N-terminally EGFP labeled E265 with a C
concentrations.  CpdR concentration was saturating at 2.5uM in all reactions that it was present.  
Other reaction conditions: ClpX 0.2uM, ClpP 0.4uM, ATP 4mM, 75ug/ml Creatine Kinase, 5mM 
Creatine Phosphate, GTP 1mM.
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Michaelis-Menten curves of initial degradation rates of an 
-terminal ssrA degradation tag at increasing 
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CHAPTER 3 
STRUCTURAL COMPONENTS OF THE PAS DOMAIN 
 To find out why the PAS domain is necessary and sufficient for degradation, we 
investigated the domain structurally.  PAS domains contain very little sequence 
homology, and are therefore difficult to characterize through alignment.  However, most 
PAS domains have similar structural characteristics.Some of the common structural 
characteristics are a multi-stranded beta sheet core and a ligand binding site(13).In 
collaboration with the Garman lab,I crystallized G130, phased with mercury compounds, 
and solved the structure to 1.7 Angstrom resolution (Table 1).  
Table 1: Crystallographic Statistics 
Space group C121 
Cell dimensions    
a, b, c (Å) 63.8,41.9,48.7 
    α, β, γ  (°)  90, 90, 107.5 
Resolution (Å) 1.7(1.74-1.70) * 
Rmerge 7.4(37.7) 
I /σI 32.8(2.35) 
Completeness (%) 84(28) 
Redundancy 10.3(5.8) 
 
 
Refinement  
Resolution (Å) 1.7 
No. reflections 10920 
Rwork / Rfree 0.19/0.22 
No. atoms  
    Protein 887 
    Water 119 
B-factors  
    All atoms 14.3 
R.m.s deviations  
    Bond lengths (Å) 0.007 
    Bond angles (°) 1.1 
*highest resolution shell in parentheses 
The structure showeda five-stranded beta sheet core and a possible binding pocket 
flanked by two alpha helices (Figure 9b and c).  These propertiesindicatethat the N-
terminal domain of PdeA is indeed a PAS domain. Only one copy of the protein was 
 present in the asymmetric unit
related monomers.  At the interface between the two monomers was a 24 amino acid long 
N-terminal alpha helix that appeared responsible for 
a.
b.
Figure 9: Characteristics of
domain dimerization. b. & c.) The PAS domain can be identified as such by a 5
core (b. in red) and 2 flanking surface 
binding operation.  d.) A unique N
domain dimerization. 
 
 To validate that the N
another truncation of PdeA with the first 24 amino 
compared the UV-trace from a gel filtration experiment of 
PdeA.  In Figure 5, gel filtration traces indicate that native PdeA elutes as a dimer, 
while∆N elutes as a monomer.  This evidence strongl
13 
; however a dimer was formed betweencrystallographically 
thisdimerization. 
c. d.
 the PAS Domain: a.) Image of crystal packing indicated PAS 
α-helices (c. in red) that could be involved in a small 
-terminal helix (in red) which appears to be responsible for 
-terminal helix was responsible for dimerization, we made 
acids removed (∆N-PdeA
∆N-PdeA to that of native 
y suggests that the N
 
 
-stranded β-sheet 
ligand 
).  We then 
-terminal helix 
 is the main structural element for
towildtype PdeA (Figure 10), dimerization cannot be critical for either substrate 
recognition by ClpXP or adaptor binding.
a.
b.
d.
Figure 10: N-terminal Helix is Responsible for PAS Domain Dimerization: 
trace comparison of WT PdeA and 
dimer, while ∆N-PdeA elutes at a volume closer to that of a monom
standards marked at top of graph.  Apparent molecular weights calculated from column standard 
curve of 6 different proteins. b. & c.) Different views of PAS domain dimers.  Note the interface 
between N-terminal helices on each 
similar rate of protein degradation.
75ug/ml Creatine Kinase, 5mM Creatine Phosphate, 1mM GTP, 2.5uM CpdR, 2.5uM Protein
 
 The question I wanted 
the PAS domain interacted with CpdR.  
the PAS domain.  I did a multiple sequence alignment
14 
 PdeA dimerization.  As ∆N-PdeA is degraded similarly 
 
 
 
c.  
 
∆N.  WT PdeA elutes at a volume closely representative of a 
er.Relevant molecular weight 
monomer.  d.) Degradation assay of PdeA vs.
Reaction contents: 0.4uM ClpX(6), 0.8uM ClpP, 4mM ATP, 
to address through this crystal structure was
I addressed this question through mutagenesis of 
 of the C.crescentus
a.) Gel filtration 
∆N.  Note the 
 
 what part of 
 PdeA PAS 
 domain with homologous proteins in other 
conserved among the proteins except for one arginine that corresponded to R69 in the 
PdeA PAS domain.  After investigation of the PAS domain crystal structure, I found that 
R69 was also a surface residue(Figure 11). I
(mutant called R69A).The rate of R69A degradation is much 
(Figure 11).  While slow, 
an interaction between the two still occurs
Figure 11: R69A Heterodimerization 
of WT PdeA. (top) Images of SDS
(bottom) Image band density quantification of SDS
Time(min). Reaction contents: 0.4uM ClpX(6), 0.8uM ClpP, 4mM ATP, 75ug/ml Creatine 
Kinase, 5mM Creatine Phosphate, 1mM GTP, 2.5uM CpdR, 2.5uM Protein construct
comparison as in a. of R69A degradation rate to that of R69A pre
equimolar amounts of G130. (top) Images of SDS
15 
alpha-proteobacteria.  Few residues were 
 decided to mutate arginine 69 to alanine 
lessthan that of native PdeA 
R69A is still degraded in a CpdR-dependent fashion, indicating 
 but is significantly compromised
d.  
in vitro: a.) Comparison of R69A degradation rate to that 
-PAGE visualization of R69A band in degradation
-PAGE results plotted as [Protein] vs. 
-incubated overnight with 
-PAGE visualization of R69A band in 
.   
 
 assays. 
 b.) Similar 
16 
 
degradation assays with and without equimolar G130. (bottom) Quantification as described 
above. Reaction contents are otherwise the same as in a. c.) Model of R69A heterodimerization.  
(top) A PdeA homodimer can successfully bind CpdR and be degraded.  (middle) A R69A 
homodimer (red) binds CpdR less well and therefore cannot be degraded in the same way as WT.  
(bottom) A PdeA-R69A heterodimer allows CpdR binding and degradation of both WT and 
R69A. d.)Structure of PAS domain with R69A colored red. 
 
It was unclear whether the decrease in degradation rate could be attributed to a 
deficiency in CpdR binding or a structural defect in R69A thatcaused it to be degraded 
more slowly than WT PdeA.  To formally rule out a structural defect, I tested whether 
R69A could heterodimerize with G130 (the isolated PAS domain).  The heterodimer of 
R69A and G130 would therefore have one monomer which could bind CpdR (G130) 
efficiently, and one monomer that could not (R69A).  I compared the disappearance of 
R69A in the presence and absence of G130.  R69A was degraded faster (Half-lives:          
–G130:~250min, +G130:~140min) in the presence of G130, indicating that R69A had 
heterodimerized with G130 and was degraded more efficiently.  If the degradation rate 
had not increased under these conditions, I would have attributed the slower degradation 
rate of R69A to an internal structural defect that caused ClpXP degradation to be 
inhibited.  This increase I saw in degradation rate could be attributed to the G130 
monomer binding CpdRfacilitating delivery of itself and the associated R69A to ClpXP.   
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CHAPTER 4 
EFFECTS OF PDEA DEGRADATION CHANGES IN THE CELL 
 Due to the importanceof PdeA in cell-cycle progression, division and motility, I 
observed the effects of my PdeAconstructs on motility in vivo.  Motility of C.crescentus 
cells can be visualized by inoculation of cells in a low percent agar plate of the 
appropriate media.  Submerging a colony into the agar via pipet tip causes the cells to 
grow in a circular pattern with a circumference of a size proportional to cell motility.  
The more motility a given cell line has, the larger the circumference.   
I made cell lines of WT C.crescentuscontaining a plasmid DNA with our protein 
constructs of interest under a xylose inducible expression system. Additionally, I made 
∆PdeA cell lines with the same set of constructs.The plasmid contained constructs PdeA, 
∆N, ∆PAS, R69A and PdeA-DD.  I then subjected each line to a set of high expressing 
and low expressing motility tests.  In these tests, when xylose is present, there is a high 
amount of expression.  When xylose is not present there is still a low level of expression 
of the protein.  The results were compared to colonies grown from WT cells expressing 
wildtype PdeA added which acted a control for normal motility.  Results were also 
compared to a ∆PdeA cell line as a control for low motility (Figure 12). 
 Figure 12: Effects of PdeA Constructs on Cellular Motility: 
a given protein construct in high expression or low expression conditions. (bottom) Grap
image quantification of colony area normalized to WT area.
 
These sets of testsallow us to draw several important conclusions.  Comparing the 
high motility control to the low motility control, we can roughly equate PdeA
functionality to motility.  Since there is high motility when PdeA is present and low 
motility when PdeA is absent, this suggests PdeA function is a determinant of motility.  
When comparing high expression of PdeA to low expression in both WT and 
lines, we see roughly the same motility.  This suggests that even low levels of WT PdeA 
can be functional enough to yield high motility.
Unlike WT, when comparing high expression of 
cells, we see a difference inmotility.  W
resembles that of a low motility strain.  However, 
motility.  This suggests that the 
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from in vitro tests that ∆N is a monomeric form of PdeA.  The results of this motility test 
can additionally mean one of two things.  High expression of monomeric PdeA drives 
either functional recovery or dimerization resulting in an almost WT motility. 
Neither high nor low expression of ∆PAS in ∆PdeA cells can recover motility.  
We know from in vitro and in vivo tests that ∆PAS cannot be degraded.  This result 
brings to light three distinct possibilities: degradation of PdeA is required for correct 
function, the PAS domain is required for PdeA function independent of degradation, or 
some combination of both.  To address these possibilities,IexpressedPdeA-DD(which 
cannot be degraded, but contains an intact PAS domain). Expression of PdeA-DD 
resultsinhigh motility underlow expressing conditions and low motility underhigh 
expressing conditions. Therefore the PAS domain is not only necessaryfor proper 
degradation of PdeA, but also plays a role in PdeA function. 
Finally, the PdeA-DD result suggests that too much PdeA can negatively affect 
motility.  Since PdeA-DD cannot be degraded, its function in the cell never ceases.  This 
means cyclic-di-GMP is constantly being degraded by PdeA-DD, and ultimately results 
in low motility as we can see in the high expression result in both WT and ∆PdeA cells.  
Low expression allows for some breakdown of cyclic-di-GMP by PdeA-DD but not too 
much, yielding high motility. 
When testing the R69A mutant in ∆PdeA cells, I saw the same results as in the 
PdeA-DD tests.  This result is in agreement with our invitro studies.  We know that the 
R69A is degraded at a very slow rate in vitro, and that PdeA-DD is not degraded.   The 
motility results of R69A therefore mimic those of PdeA-DD. The same conclusion can be 
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reached that R69A is functional and healthy for the cell in low levels, but too much can 
yield low cell motility. 
The motility results of R69A in WT cells appear to validate the in vitro 
heterodimerization tests.  High expression of R69A in ∆PdeA cells shows lower motility 
than that of high expression of R69A in WT cells.  Since WT cells contain a native 
version of PdeA that has normal CpdR binding capacity, this suggests when some of the 
R69A heterodimerizes with the WT PdeA both species are degraded.  The degradation of 
the heterodimers serves to partially recover motility even in high expression levels of 
R69A. 
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CHAPTER 5  
CONCLUSIONS 
 Over the course of this study, I have studied PdeA degradation using techniques 
in the fields of molecular biology, structural biology and cellular biology.  Therefore, 
there are many conclusions we can draw regarding PdeA degradation that paint a 
captivating picture. 
 We now know that a PdeA dimer is degraded in a CpdR-dependent fashion from 
C to N-terminus.  Degradation of PdeA initiates when CpdR binds to an N-terminal PAS 
domain and delivers PdeA to ClpX for recognition. A key residue in CpdR binding is 
R69A, which lies at the top of a unique PAS domain structural motif.After recognition, 
PdeA undergoes processive degradation which, if interrupted at any point, allows for 
reengagementto ClpX regardless of the resulting c-terminal residues.  Additionally, if 
degradation of PdeA does not occur properly then cells suffer motility deficiencies.  
Proper degradation and function of PdeA in the cell is dependent on activity of the PAS 
domain and dimerization via an N-terminal helix.  Therefore, these deficiencies may lie 
in improper regulationof PdeA function via degradation.   
 With this understanding of PdeA degradation and the structure of the PAS domain 
in hand we can now address new questions.  Why is normal motility of the cell so directly 
related to PdeA function and degradation?  PAS domains normally bind some ligand - 
Does the possible ligand binding site play a role in PdeA function?  Is CpdR a ligand?  Is 
the PAS Domain capable of interacting with more than just CpdR?  Why can PdeA so 
readily reengage ClpX?   
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Proteolysis of PdeA is serving as a direct regulator of integral morphological 
features during cell division.  It is very possible that PdeA falls within a pathway of 
enzymes and metabolites that regulate key functions for motility adaptation.  Such a 
pathway could entertain large complexities due to the involvement of CpdR and the 
functionality in the PAS domain.  The PAS domain responds to signals from a regulatory 
adapter and also plays a role in advancing proper cell growth.  PAS domains could 
therefore have an important role in communication between posttranslational regulators 
and proteins associated with cell division.  Furthermore, PdeA activity is regulated by its 
degradation.  Linking the N-terminal PAS domain that binds adaptors to a C-terminal 
degradation tag means PdeA is able to reengage ClpX during partial processing.  This 
leads me to believe that proper destruction of PdeA may also have an unknown purpose 
in the proper cell growth.  Careful study of the underlying determinants of PdeA 
degradation, as well as its interconnectivity with cell cycle progression could greatly 
deepen our capability of understanding the purpose and mechanisms of proteolytic 
regulation.  
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CHAPTER 6  
MATERIALS AND METHODS 
6.1 Material Nomenclature 
6.1.1 Buffers 
1,)Lysis Buffer: 50mM Tris pH 8.0, 300 mM NaCl, 10% Glycerol, 10 mM Imidazole  
2.)Elution Buffer: 50mM Tris pH 8.0, 300 mM NaCl, 10% Glycerol, 300 mM Imidazole 
3.)H-buffer: 25mM HEPES pH 7.5, 100mM KCl, 10mM MgCl2, 10% (v/v) Glycerol 
6.1.2 Media 
1.)LB (Luria Broth): 1% (w/v) Bacto-Tryptone, 1% (w/v) NaCl, 0.5% (w/v) yeast extract 
2.)PYE:0.2% (w/v) peptone, 0.1% (w/v) yeast extract, 0.5 mM CaCl2, 0.8 mM MgS04 
3.)Motility plates: 0.2% (w/v) peptone, 0.1% (w/v) yeast extract, 0.5 mM CaCl2, 0.8 mM 
MgS04, 0.3% (w/v) Agar, 0.2% (v/v) Xylose (present only in high expression plates) 
6.1.3 Western Blotting 
1.)Primary antibody: Monoclonal ANTI-FLAG® M2 antibody produced in mouse 
2.)Secondary antibody: Goat Anti-Mouse IgG, HRP Conjugate polyclonal antibody 
(Millipore, Cat# 12-349) 
Apparatus: Hoefer TE70X Semi-dry Transfer Unit 
6.2 Protein Purification 
6.2.1 HisSUMO tagged Proteins 
6.2.1.1 Grow-up and Initial Purification Step 
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 Included in the HisSUMO tagged set are PdeA, PdeA-DD, CpdR, R69A, R280, 
E265, G130, L131-E265, ∆N, and ∆PAS.  All HisSUMO tagged proteins are expressed 
using the pET23b vector under the T7 Promoter system.  Immediately downstream of the 
promoter is the HisSUMO sequence which adds a 6-histidine tag attached to a small 
protein adapted for solubility enhancement.  Protein constructs are inserted downstream 
of the HisSUMO tag and the resulting proteins are produced with an N-terminal 
HisSUMO tag that can be used for Ni-NTA column affinity.  The HisSUMO tag is also 
cleavable by the Ulp1his enzyme.  The tag can therefore be used to retain the protein on a 
nickel-NTA purification column and then later be excised for experimental purposes.  All 
vectors were transformed into BL21 cells for high expression purposes. 
 2 days prior to purification, an overnight culture in appropriate volume of LB with 
100ug/ml Ampicillin was started.  The pET23 vector contains a cassette for Ampicillin 
resistance. 10 ml of overnight cell cultures containing the vector of interest was started 
for every liter grown up the following day.  Cultures were incubated at 37oC. 
  The following day, 10 ml of overnight culture was added for every liter (1:100 
dilution) of cells grown up in fresh media containing the same ingredients as the 
overnight media.  4-6 liters were incubated at 37 oC shaking at 250 RPM until growth 
reached an OD600 between 0.4 and 0.8.Cultures were then induced by adding 0.4 mM 
IPTG and allowed to continue shaking for 3-5 hrs.  Induction with IPTG turns on a T7-
Promoter region on the pET23 vector that initiates constitutiveexpression of the 
downstreram protein.   Cells were pelleted at 6,000 x g for 15 minutes.  Supernatant was 
discarded and pellets were resuspended in Lysis buffer (7.5ml buffer for each 0.5 L of 
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pellet.  The lysis buffer is used as a resuspension agent because it is effective for lysis of 
the cells and purification purposes.  Pellets were then frozen at-80 oC until the next day. 
 On the next day, a Ni-NTA column was poured, 1 ml bed for every 1 L of cells 
prepped and equilibrated into lysis buffer.  Equilibration into the correct buffer is 
required or else the protein could aggregate on the column.   Cell pellets from above were 
thawed and lysed using a microfluidizer under 14,000psi of pressure. Lysate was then 
pelleted at 15,000 x g for 20 minutes.   Supernatantwas saved separately and pellet was 
discarded.  The purpose of these steps is to break apart cells to expose proteins, and also 
to separate the cell debris from components in solution.   
Ni resin was resuspended with a small amount of lysis buffer and added to lysate 
supernate and then allowed to shake gently at 4 oC for one hour.  During this time, the 
proteins in solution that react with Ni will bind to the resin.  It is important to take care in 
not disturbing the mixture too much at this point and keep the temperature cold.  
Otherwise, protein aggregation could occur.Resin was spun down in a tube at 1,000 x g 
for 5 minutes and supernatent was collected as a Flow-through sample.  Resin pellet was 
resuspended in a small amount of lysis buffer and poured back into a column.  Column 
was then washed with at least 25X column volumes of Lysis buffer and wash is collected.  
This wash serves to separate weakly bound proteins that are not HisSUMO tagged, from 
the resin.  Protein is eluted from the column by adding 2 x 1.25 columnvolumes of 
elution buffer and collected.  The elution buffer contains a high amount of Imidazole 
which binds in place of histidine residues, allowing for the tagged protein to elute from 
the column.  Elutions are concentrated or diluted to 2.5ml (for buffer exchange purposes) 
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and buffer exchanged (protocol 6.10) into either lysis buffer for further purification as in 
protocol 6.2.1.2 or into H-buffer for various testing purposes. 
6.2.1.2 HisSUMO Cleavage and Secondary Purification Step 
 After buffer exchange into lysis buffer, at least 75ul of >100uM Ulp1his was 
added to SUMO-tagged protein and incubated at 4 oC overnight.  During this time, 
Ulp1his is cleaving the HisSUMO tag from the protein.  The next day, cleaved protein 
was applied to a 2 ml (bed volume) of Ni-NTA resin.   Flowthrough was collected and 
passed over column again.  This final flowthrough contains untagged protein thatcan be 
concentrated to 2.5ml and buffer exchanged (protocol 6.9) into H-buffer for testing 
purposes. 
 To recover remaining cleaved HisSUMO tag or HisSUMO tagged protein the 
following steps were executed.  Add 2x3ml of Lysis Buffer to column and collect.  Add 
5ml of Elution Buffer to column and collect.  This elution will contain cleaved HisSUMO 
tag or HisSUMO tagged proteinthatcan be buffer exchanged into H-buffer or other buffer 
for testing purposes. 
6.2.2 ClpX 
The purification of this protein followed steps noted in the methods section of reference 
3. 
6.2.3 Native ClpX 
The purification of this protein followed steps noted in the methods section of reference 
3.   
6.2.4 ClpP 
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The purification of this protein followed steps noted in the experimental procedures 
section of reference 7.  All aspects are the same except the ClpP expressed was expressed 
using a pQE70 vector. 
6.3In vitro degradation assay 
 Degradation assays final concentrations were as follows unless noted otherwise:  
ClpX 0.4uM, ClpP 0.8uM, ATP 4mM, 75ug/ml Creatine Kinase, 5mM Creatine 
Phosphate, GTP 1mM, substrate 2.5uM, CpdR 2.5uM (if present).  Reaction components 
are mixed and extra volume is filled with H-buffer. H-buffer provides an environment in 
which the ClpXP machinery can function correctly. In the absence of CpdR, the volume 
of protein is substituted with H-buffer.  Reaction is begun by adding ATP, Creatine 
Kinase, and Creatine Phosphate to a master mix containing ClpX, ClpP and GTP.  All 
reactions are carried out at 30 oC. 
6.4 In vivo degradation assay 
 Strains were expressed in a 477Caulobacter cell line inducible with xylose and 
contained either WT genes or WT genes lacking a native PdeA (∆PdeA cells) gene.  
50ml cultures containing these cell lines were grown up under inducing conditions 
overnight.  The next day, cultures were back diluted to the sameOD600 and allowed to 
grow another 90 minutes. The culture was then divided in half and cells were pelleted in 
separate tubes.  One pellet was resuspended in 10ml of inducing media, while the other 
was resuspended in 10ml of media containing glucose to turn off protein induction.  
500ul samples were taken from cultures at each timepoint then spun down at 4,000 x g.  
Supernate was disregarded and pellet was immediately frozen in dry ice.  These pellets 
were later resuspended in 2X SDS, spun down at 15,000 x g and heated at 65oC before 
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loading onto an SDS-PAGE gel.  Protein was visualized using western blotting 
techniques and the antibodies listed in 6.1.3. 
6.5 EGFP degradation assay 
 This assay was done using an N-terminally EGFP labeled substrate.  The 
degradation reaction is carried out in a black 384 well plate treated with a non-stick 
protein compound using a SpectraMax M5.  Readings are taken with an excitation 
wavelength between 444 and 460 and an emission wavelength between 540and 545.  
 Degradation assays final concentrations were as follows unless noted otherwise:  
ClpX 0.2uM, ClpP 0.4uM, ATP 4mM, 75ug/ml Creatine Kinase, 5mM Creatine, GTP 
1mM, substrate 2.5uM, CpdR 2.5uM (if present).  Reaction components are mixed and 
extra volume is filled with H-buffer.  In the absence of CpdR, the volume of protein is 
substituted with H-buffer.  Reaction is begun by adding ATP, Creatine Kinase, and 
Creatine Phosphate to a master mix containing ClpX, ClpP and GTP.  All reactions are 
carried out at 30 oC.   
6.6Crystal Tray Setup 
6.6.1 Sitting Drop 
 A single 96-well crystal screen was done using G130 diluted into water to 
determine initial crystallization conditions.  G130 was purified as in 6.2.1 and 
subsequently concentrated down then diluted into MilliQ H2O filter sterilized in a 0.22 
micron Millex sterile syringe filter.  Concentration of G130 was done using a 
5,000MWCO Vivaspin 500 tabletop centrifuge concentrator.  A sample of volume of 
G130 would be reduced approximately 10-fold and diluted back to original sample 
volume with H2O up to at least 5 times to dilute out original buffer. 
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 G130 was then concentrated a final time to a concentration of no less than 6.26 
mg/ml and 1 ul was put into each 2/3of a Corning 96 Well COC Protein Crystallization 
Microplate with 3:1, 2µL Conical Flat Bottom Wells in each.  Each reservoir was filled 
with a corresponding number solution from the Qiagen JCSG+ Suite.   
E.g.: Reservoir A1 corresponds to solution 1, Reservoir A2 corresponds to solution 2, 
Reservoir B1 Corresponds to solution 13 etc. 
 1ul of the reservoir solution in each block was put into each of the 3 wells in a 
block.  Then, one well additionally had 1ul of the protein sample with highest 
concentration from the concentrated stock. A second well additionally had 1ul of protein 
that was mixed in a 1:1 ratio with H2O.  The third well in each block additionally had a 
control well for 1ul of protein at a lower concentration or buffer alone. 
 All reservoir solutions were pipette in row-by-row using a 10 barrel multi-channel 
automated pipette with 50ul of solution in each reservoir.  Then all columns but the 
leftmost one was then covered with a piece of parafilm.  The wells of one exposed row 
were then filled with 1ul of the reservoir solution taken from the reservoir in the same 
block using a manual pipette pressing the plunger down until the first stop (never fully 
expelling liquid past the first stop).  Subsequently, the appropriate protein samples were 
pipetted into the wells manually in the same fashion. 
The ideal crystallization condition in the screen was B7, 0.1M Sodium Acetate pH 
4.6 and 8% (w/v) PEG 4,000 incubated at 20 oC.  After a successful screen, hanging drop 
plates were assembled to scale-up and optimize crystal growth. 
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6.6.2 Hanging Drop 
 Hanging drop crystal plates were set up 4 x 6 pre-greased hanging drop plates.  
Three drops were set up using a manual pipet on a glass cover slip.  Drops were set-up as 
described in 6.6.1 with the same ratio of protein solution to reservoir solution.  The same 
concentrations of G130 were used as in 6.6.1.   
Reservoir solutions were set up individually based on the condition being tested.  
Stock solutions of individual components were made and filtered with a 0.22um filter 
before tray set up.  Each component was manually pipetted into the reservoir individually 
prior to drop setup.  Optimal crystal conditions for G130 growth were 0.1M Sodium 
Acetate pH 4.5 and 4% (w/v) PEG 4,000 incubated at 20 oC. 
Phasing was done using a Mercury Acetate (Hampton Research) solution which 
targets deprotonated cysteins and thus reacts better at higher pH values.  Crystals were 
therefore alternatively grown up in 0.1M HEPES pH 7.5 and 4% (w/v) PEG 4,000 
incubated at 20 oC.  After crystals were grown, 5 microliters of a solution containing 
0.1M HEPES pH 7.5 and 4% (w/v) PEG 4,000 and 10mM Mercury Acetate was added to 
the crystal drop directly.  Crystals were allowed to incubate another 24 hours at 20 oC 
before X-ray treatment. 
6.7 Gel Filtration 
 Gel filtration experiments were done using a GE ATKA Purifier UPC 10 FPLC 
with a GE Superdex 75 10/300 GL (Instruction #71-5017-96 AF).  The column was 
equilibrated with H-buffer prior to protein injection.  110ul of a pure protein sample at a 
given concentration were loaded onto a 100ul loop and injected over the Superdex 75.  
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Pump flow was 0.5ml/min with an initial pump of 1ml through the system itself before 
column injection.  Fractions were collected in 500ul samples for 24mls.  Elution volumes 
of a set of 6 standards were fit to alogarithmic curve and molecular weight of injected 
samples were compared to this set to estimate molecular weight. 
 
6.8 Heterodimerization Degradation Assay 
6.8.1 In vitro Heterodimerization Degradation Assay 
 Same steps taken here as in 6.3 except protein sample was a protein sample at 
equimolar concentrations of R69A and G130 incubated in an eppendorf tube at room 
temperature overnight prior to set up of the assay. 
6.8.2 In vivo Heterodimerization Degradation Assay 
 Same steps taken here as in 6.4 except WT CB15N cells with R69A expressed in 
a 477 vector were subjected to the assay in tandem with ∆PdeA CB15N with R69A 
expressed similarly. 
6.9 Motility Assay 
 Cells expressing a given construct in the 477 vector(spectinomycin resistant, 
medium copy, xylose promoter containing plasmids) were used in this assay.  At least 
one colony of cells was scooped manually onto the end of a pipet tip and stabbed straight, 
half way to the bottom of a plate containing 0.3% PYE Agar with 50ug/ml 
Spectinomycin. The agar either included no added sugars or 0.2% Xylose to induce 
protein expression.  Plates were then incubated at 30 oC for up to 4 days. 
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Table 2: Table of Strains and Plasmids 
Index Number Cell Line Vector Antibiotic Selection Growth Medium 
KRPC1 WTCB15N 477 PdeA Spectinomycin PYE 
KRPC2 WTCB15N 477 ∆N Spectinomycin PYE 
KRPC3 WTCB15N 477 ∆PAS Spectinomycin PYE 
KRPC4 WTCB15N 477 PAS Spectinomycin PYE 
KRPC5 WTCB15N 477 PdeA-DD Spectinomycin PYE 
KRPC6 WTCB15N 477 R69A Spectinomycin PYE 
KRPC7 ∆PdeACB15N 477 PdeA Spectinomycin PYE 
KRPC8 ∆PdeACB15N 477 ∆N Spectinomycin PYE 
KRPC9 ∆PdeACB15N 477 ∆PAS Spectinomycin PYE 
KRPC10 ∆PdeACB15N 477 PAS Spectinomycin PYE 
KRPC11 ∆PdeACB15N 477 PdeA-DD Spectinomycin PYE 
KRPC12 ∆PdeACB15N 477 R69A Spectinomycin PYE 
KRPC13 ∆PdeACB15N 477 GFP-ssrA Spectinomycin PYE 
KRPC14 E.coli Top10 pET23SUMO PdeA-DD Ampicillin LB 
KRPC15 E.coli Top10 pET28 EGFP-E265-ssrA Ampicillin LB 
KRPC16 E.coli Top10 pET28 EGFP-E265-AVAA Ampicillin LB 
KRPC17 E.coli Top10 pET23SUMO E265 Ampicillin LB 
KRPC18 E.coli Top10 pET23SUMO S82-R280 Ampicillin LB 
KRPC19 E.coli Top10 pet23SUMO L131-E265 Ampicillin LB 
KRPC20 E.coli Top10 pet23SUMO PAS Ampicillin LB 
KRPC21 E.coli Top10 pet23SUMO ∆N Ampicillin LB 
KRPC22 E.coli Top10 pet23SUMO ∆N-G130 Ampicillin LB 
KRPC23 E.coli Top10 pet23SUMO R69A Ampicillin LB 
KRPC24 E.coli Top10 pet23SUMO PdeA-ssrA Ampicillin LB 
KRPC25 E.coli Top10 pet23SUMO E265-ssrA Ampicillin LB 
KRPC26 E.coli Top10 pet23SUMO ∆PAS Ampicillin LB 
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CHAPTER 7 
RELEVANT TERMS 
Term Description 
GGDEF 
Domain 
A protein domain with diguanylate cyclase activity characterized by an 
active site containing the amino acid sequence GGDEF.  GTP can bind 
on the GGDEF motif.  The characteristic activity of this domain results in 
the cyclization of two molecules of GTP into one of cyclic-di-GMP. 
GEDEF 
Domain 
A protein domain characterized by a GTP binding site containing the 
amino acid sequence GEDEF.  Binding of GTP to this domain can serve 
to allosterically activate an alternative EAL domain.  This domain is 
unable to cyclize GTP into cyclic-di-GMP and is therefore referred to as 
“degenerate”. 
EAL 
Domain 
A protein domain with diguanylate phosphodiesterase activity 
characterized by a conserved amino acid seqeuence motif EAL.  Cyclic-
di-GMP can bind to this domain.  The characteristic activity of this 
domain results in the linearization of one molecule of cyclic-di-GMP into 
pGpG. 
PAS 
Domain 
A protein domain that can function as a signal sensor and ligand binding 
domain.  The domain is named as "PAS" for three types of proteins the 
domain occurs in: P: Per: Period Circadian Protein A: Arnt: Aryl 
hydrocarbon receptor nuclear translocator protein, S: Sim: Single-minded 
protein.  These domains generally have low sequence homology, but high 
structural homology. 
Cyclic-
di-GMP 
A small molecule involved in bacterial signal transduction.  Usually 
synthesized by cyclization of two molecules of GTP.  Upregulation or 
downregulation of cyclic-di-GMP levels in a cell can lead to alternative 
signalling events.  Levels are upregulated by diguanylate cyclases and 
downregulated by phosphodiesterases. 
 
 
 
 
34 
 
 
BIBLIOGRAPHY 
1.) Hengge R.Principles of c-di-GMP signalling in bacteria. Nat Rev Microbiol. 2009 
Apr;7(4):263-73.  
 
2.) Zhao JM, Lee H, Nome RA, Majid S, Scherer NF, Hoff WD. Single-molecule 
detection of structural changes during Per-Arnt-Sim (PAS) domain activation. Proc Natl 
Acad Sci U S A. 2006 Aug 1;103(31):11561-6. Epub 2006 Jul 19. 
 
3.) Chowdhury T, Chien P, Ebrahim S, Sauer RT, Baker TA. Versatile modes of peptide 
recognition by the ClpX N domain mediate alternative adaptor-binding specificities in 
different bacterial species. Protein Sci. 2010 Feb;19(2):242-54. 
 
4.) Iniesta AA, Shapiro L.A bacterial control circuit integrates polar localization and 
proteolysis of key regulatory proteins with a phospho-signaling cascade.Proc Natl Acad 
Sci U S A. 2008 Oct 28;105(43):16602-7. Epub 2008 Oct 22. 
 
5.) Sauer RT, Baker TA. AAA+ Proteases: ATP-Fueled Machines of Protein Destruction. 
Annu Rev Biochem. 2010 Jun 23. [Epub ahead of print] 
 
6.)Christen M, Christen B, Folcher M, Schauerte A, Jenal U.Identification and 
characterization of a cyclic di-GMP-specific phosphodiesterase and its allosteric control 
by GTP. J Biol Chem. 2005 Sep 2;280(35):30829-37. Epub 2005 Jul 1. 
 
7.) Kim YI, Burton RE, Burton BM, Sauer RT, Baker TA.Dynamics of substrate 
denaturation and translocation by the ClpXP degradation machine.Mol Cell. 2000 
Apr;5(4):639-48. 
 
8.) D'Argenio DA, Miller SI.Cyclic di-GMP as a bacterial second messenger. 
Microbiology. 2004 Aug;150(Pt 8):2497-502. 
 
9.) Lasa I. Towards the identification of the common features of bacterial biofilm 
development. Int Microbiol. 2006 Mar;9(1):21-8. 
 
10.) Jenal U.The role of proteolysis in the Caulobacter crescentus cell cycle and 
development. Res Microbiol. 2009 Nov;160(9):687-95. Epub 2009 Sep 22. 
 
11.) Schmidt R, Bukau B, Mogk A.Principles of general and regulatory proteolysis by 
AAA+ proteases in Escherichia coli. Res Microbiol. 2009 Nov;160(9):629-36. Epub 
2009 Sep 22. 
 
12.) Nager AR, Baker TA, Sauer RT.Stepwise Unfolding of a β Barrel Protein by the 
AAA+ ClpXP Protease. J Mol Biol. 2011 Jul 29. [Epub ahead of print] 
35 
 
13.) Henry JT, Crosson S. Ligand Binding PAS Domains in a Genomic, Cellular, and 
Structural Context. Annu Rev Microbiol. 2011 Jun 10. [Epub ahead of print] 
 
14.) Martin A, Baker TA, Sauer RT.Protein unfolding by a AAA+ protease is dependent 
on ATP-hydrolysis rates and substrate energy landscapes.Nat Struct Mol Biol. 2008 
Feb;15(2):139-45. Epub 2008 Jan 27. 
 
15.) Chowdhury T, Chien P, Ebrahim S, Sauer RT, Baker TA. Versatile modes of peptide 
recognition by the ClpX N domain mediate alternative adaptor-binding specificities in 
different bacterial species. Protein Sci. 2010 Feb;19(2):242-54. 
 
16.) Román-Hernández G, Hou JY, Grant RA, Sauer RT, Baker TA.The ClpS Adaptor 
Mediates Staged Delivery of N-End Rule Substrates to the AAA+ ClpAP Protease. Mol 
Cell. 2011 Jul 22;43(2):217-28. 
 
17.) Farrell CM, Baker TA, Sauer RT.Altered specificity of a AAA+ protease.Mol Cell. 
2007 Jan 12;25(1):161-6. 
 
18.) Keiler KC, Silber KR, Downard KM, Papayannopoulos IA, Biemann K, Sauer 
RT.C-terminal specific protein degradation: activity and substrate specificity of the Tsp 
protease.Protein Sci. 1995 Aug;4(8):1507-15. 
 
19.) Gottesman S, Roche E, Zhou Y, Sauer RT.The ClpXP and ClpAP proteases degrade 
proteins with carboxy-terminal peptide tails added by the SsrA-tagging system.Genes 
Dev. 1998 May 1;12(9):1338-47. 
 
20.) Kenniston JA, Baker TA, Sauer RT.Partitioning between unfolding and release of 
native domains during ClpXP degradation determines substrate selectivity and partial 
processing.Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1390-5. Epub 2005 Jan 25. 
 
 
